Positive impact of sulfamethoxazole-trimethoprim prophylaxis on prevention of severe infections in a patient with glycogen storage disease type Ib
Objective Glycogen storage disease type Ib (GSD-Ib) is a very rare disease complicated by neutropenia with consequent recurrent bacterial infections. Treatment with Filgrastim is not always effective. The low CD4 count observed in our patient is likely the underlying cause of this treatment failure. This low value was previously examined in a small-scale study. Therefore, adding sulfamethoxazole-trimethoprim (SMX-TMP) might be a good strategy. Methods We present the case of a male patient with GSD-Ib. He has severe neutropenia (380/$ mm^{3} $) with recurrent infections. Despite neutrophil improvement with Filgrastim, he developed three severe infections requiring hospitalization. Lymphocyte phenotyping showed a deficit in T CD4 + cells (280/$ mm^{3} $) which led us to HIV testing returning negative. Based on this finding we initiated prophylaxis with SMX-TMP. Results Since the start of SMX-TMP along with Filgrastim, the patient was not admitted to the hospital for any bacterial infection. Conclusion To date, no study has examined the significance of incorporating antibiotic prophylaxis for neutropenic patients with GSD-Ib based on CD4 count, akin to the approach of adding SMX-TMP to antiretroviral therapy for HIV patients. Cotrimoxazole is empirically prescribed without assessing the CD4 count or conducting a comparative analysis of the advantages of its addition to Filgrastim. Such practices could potentially exert a significant influence on the disease’s presentation and severity..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Journal of Rare Diseases - 2(2023), 1 vom: 04. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khalil, Marina-Antoinette [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Gene |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s44162-023-00023-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053965000 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053965000 | ||
| 003 | DE-627 | ||
| 005 | 20231204064608.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231204s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s44162-023-00023-w |2 doi | |
| 035 | |a (DE-627)SPR053965000 | ||
| 035 | |a (SPR)s44162-023-00023-w-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khalil, Marina-Antoinette |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Positive impact of sulfamethoxazole-trimethoprim prophylaxis on prevention of severe infections in a patient with glycogen storage disease type Ib |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Objective Glycogen storage disease type Ib (GSD-Ib) is a very rare disease complicated by neutropenia with consequent recurrent bacterial infections. Treatment with Filgrastim is not always effective. The low CD4 count observed in our patient is likely the underlying cause of this treatment failure. This low value was previously examined in a small-scale study. Therefore, adding sulfamethoxazole-trimethoprim (SMX-TMP) might be a good strategy. Methods We present the case of a male patient with GSD-Ib. He has severe neutropenia (380/$ mm^{3} $) with recurrent infections. Despite neutrophil improvement with Filgrastim, he developed three severe infections requiring hospitalization. Lymphocyte phenotyping showed a deficit in T CD4 + cells (280/$ mm^{3} $) which led us to HIV testing returning negative. Based on this finding we initiated prophylaxis with SMX-TMP. Results Since the start of SMX-TMP along with Filgrastim, the patient was not admitted to the hospital for any bacterial infection. Conclusion To date, no study has examined the significance of incorporating antibiotic prophylaxis for neutropenic patients with GSD-Ib based on CD4 count, akin to the approach of adding SMX-TMP to antiretroviral therapy for HIV patients. Cotrimoxazole is empirically prescribed without assessing the CD4 count or conducting a comparative analysis of the advantages of its addition to Filgrastim. Such practices could potentially exert a significant influence on the disease’s presentation and severity. | ||
| 650 | 4 | |a Glycogen storage disease Ib |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neutropenia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Infection prophylaxis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a gene |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Fata, Anthony |4 aut | |
| 700 | 1 | |a Diab, Ernest |4 aut | |
| 700 | 1 | |a Raad, Elie |4 aut | |
| 700 | 1 | |a Wehbe, Amine |4 aut | |
| 700 | 1 | |a Megarbane, Andre |0 (orcid)0000-0003-0714-2469 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Rare Diseases |d Springer Berlin Heidelberg, 2023 |g 2(2023), 1 vom: 04. Dez. |w (DE-627)SPR049512951 |x 2731-085X |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2023 |g number:1 |g day:04 |g month:12 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s44162-023-00023-w |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2023 |e 1 |b 04 |c 12 | ||